Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > The time is coming [WITH LINKS]

<< Previous

Bullboard Posts

Next >>

Comment by Antonius2on May 02, 2021 9:06pm

106 Views

Post# 33111970

RE:RE:The time is coming [WITH LINKS]

In addition to vaccine hoarding by rich countries and vaccine hesitancy in general - is the notion that in countries that are generally poorer with less robust logistics and many undocumented/rural individuals - a therapeutic drug will be the route out of this Covid dilemma. In addition to providing Covid support Arch will be delivering assistance to those suffering from acute kidney injury for which there is no meaningful drug currently in existence. The time is now.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec